ClinicalTrials.gg
RecruitingNCT07616934Updated Jun 16, 2026

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults

A Phase 1 interventional study of Placebo and VAX-A1 Low in Group A Streptococcal Infection, sponsored by Vaxcyte, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Vaxcyte, Inc. · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.

02

Conditions studied

  • Group A Streptococcal Infection

Keywords

  • Strep A
  • Streptococcus pyogenes
  • Safety
  • Reactogenicity
  • Immunogenicity
  • Healthy Adults
  • Australia
03

In context

Streptococcal Infections

147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.

This study's planned enrollment of 80 is below the median of 270 across 106 interventional studies indexed under Streptococcal Infections.

Browse Streptococcal Infections studies →

Lead sponsor

Vaxcyte, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals 18-40 years of age (inclusive) at the time of randomization into the study
  • Able and willing to complete the process
  • Available for clinical follow-up through the last study visit at 6 months post-Dose 2
  • Willing to have blood samples collected, stored indefinitely, and be used for research purposes
  • Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process
  • Healthy, as defined by absence of medical condition, either acute or chronic, as determined by medical history, vital signs, physical examination, screening laboratory test results, TTE and results, and clinical assessment by the Investigator
  • For applicable individuals, (as confirmed by follicle-stimulating hormone [FSH] level at Screening) for at least 1 year, or surgically sterile for at least 6 months prior to dosing
  • Individuals of must be not pregnant and not lactating, must have negative urine and serum pregnancy tests at Screening and a negative urine pregnancy test immediately prior to randomization, and agree to use acceptable if heterosexually active. Participants must agree to consistently practice contraception if sexually active at least 7 days prior to enrollment and throughout the duration of the study
  • Able to access and use a smartphone, tablet, computer, or other device connected to Wi-Fi or cellular network for completion of an eDiary

Exclusion criteria

Exclusion Criteria:

  • History of any cardiac, rheumatologic, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other disease as determined by the Investigator. This includes a history of polyarthritis, nephropathy, pericarditis, myocarditis, or hypertension requiring current pharmacologic treatment.
  • History of invasive GAS infection (such as toxic shock syndrome, necrotizing fasciitis, bloodstream infection, pleural empyema, meningitis) or poststreptococcal immune mediated disease (such as RHD, ARF, or APSGN)
  • Known or suspected disease, collagen vascular disease, or impairment/alteration of immune function (e.g., congenital or acquired immunodeficiency)
  • Previous or existing diagnosis of , virus, or virus, or a positive serologic test at Screening
  • History of or neoplasm, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • Bleeding disorder diagnosed by a physician (e.g., factor deficiency, coagulopathy, or disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
  • Oral temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened)
  • Confirmed elevated BP at Screening, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg measured seated after ≥5 minutes rest and confirmed by repeat measurement
  • Physical examination indicating any clinically significant medical condition or inadequate venous access
  • Any Grade ≥2 abnormal safety laboratory test at Screening
  • Abnormal ESR, or CRP or C3 levels at Screening
  • Confirmed microscopic hematuria (>10 RBC/mm³) on UA at Screening. If a potential confounder is present, a repeat UA may be performed during the Screening window; exclusion applies to confirmed microscopic hematuria on an evaluable specimen.
  • Evidence of antecedent/recent GAS infection based on anti-DNase B titer ≥ the laboratory reported (ULN) for the assay used at Screening. Participants with anti-DNase B titer ≥0.8×ULN and \<ULN at the initial Screening visit are temporarily ineligible and may be re-screened with repeat anti-DNase B testing 7-21 days after the initial sample; participants will be excluded if the repeat anti-DNase B titer is ≥ULN or demonstrates a clinically meaningful increase of ≥20% relative to the initial screening value, in the absence of an alternative explanation.
  • Positive GAS rapid NAAT at Screening or Day 1
  • Any finding based on comprehensive TTE at Screening indicative of possible cardiac pathology, including valvular abnormalities defined as mild stenosis or regurgitation.
  • Any finding on that is indicative of possible cardiac pathology, including a prolonged PR interval or conduction abnormality
  • Receipt of any product within 30 days prior to enrollment into the study, currently participating in another study that includes receipt of an investigational product or procedure, or having plans to receive another investigational product(s) while on study
  • Planned or actual administration of any licensed vaccine within 30 days before or after receipt of study vaccine, or within 14 days before or after receipt of study vaccine in the case of influenza and COVID-19 vaccines. Vaccines that are required emergently (e.g., tetanus vaccination in a participant with a contaminated wound) may be given at any time during the study.
  • Received blood or blood product (including intravenous immunoglobulin) within 6 months of enrollment into the study
  • Receipt of any therapy, including systemic at a dosage equivalent to ≥0.5 mg/kg/day of prednisone, chronic use of inhaled or nebulized high potency corticosteroids, or use of intra-articular or intrabursal corticosteroids within 1 year of the first study vaccination
  • (BMI) ≥32 kg/m2 or ≤18 kg/m2
  • History of alcohol or drug abuse in the 5 years prior to enrollment, or any history of intravenous drug abuse
  • Any medical, psychiatric, or social condition that in the judgment of the Investigator may interfere with the study objectives, impair a participant's ability to give , pose a risk to the participant, or prevent the participant from completing the study
  • Employee of, or first degree relative of any person employed by the Sponsor, the contract research organization (CRO), the Investigator, study site personnel, or site
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    VAX-A1 Low

    Participants will receive 2 doses of VAX-A1 administered via intramuscular injection at Day 1 and Month 2

    Biological: VAX-A1 Low

  • Experimental
    VAX-A1 Mid

    Participants will receive 2 doses of VAX-A1 administered via intramuscular injection at Day 1 and Month 2

    Biological: VAX-A1 Mid

  • Experimental
    VAX-A1 High

    Participants will receive 2 doses of VAX-A1 administered via intramuscular injection at Day 1 and Month 2

    Biological: VAX-A1 High

  • Placebo comparator
    Placebo

    Participants will receive 2 doses of placebo administered via intramuscular injection at Day 1 and Month 2

    Biological: Placebo

Interventions

  • BiologicalPlacebo

    0.5mL of placebo (normal saline) will be administered into the deltoid muscle

  • BiologicalVAX-A1 Low

    0.5mL of the low dose VAX-A1 will be administered into the deltoid muscle

  • BiologicalVAX-A1 Mid

    0.5mL of the mid dose VAX-A1 will be administered into the deltoid muscle

  • BiologicalVAX-A1 High

    0.5mL of the high dose VAX-A1 will be administered into the deltoid muscle

06

What researchers measure

Primary outcomes

  1. Frequency of solicited local reactions (redness, swelling, and pain at injection site)

    Time frame: up to 7 days after each vaccination

  2. Frequency of solicited systemic adverse events (AE) (fever, headache, fatigue, muscle pain, rash, joint pain, nausea/vomiting, diarrhea)

    Time frame: up to 7 days after each vaccination

  3. Frequency of laboratory abnormalities identified from protocol-scheduled safety laboratory assessments at 7 days after each vaccination and reported as AE

    Time frame: 7 days after each vaccination

  4. Frequency of unsolicited AE

    Time frame: up to 30 days after each vaccination

  5. Frequency of medically attended AE (MAAE)

    Time frame: Up to 8 months after first vaccination

  6. Frequency of new onset chronic illness (NOCI)

    Time frame: up to 8 months after the first vaccination

  7. Frequency of serious adverse events (SAE)

    Time frame: from screening through up to 8 months after first vaccination

  8. Occurrence of AE of special interest (AESI) (acute rheumatic fever [ARF], acute carditis [AC], and acute glomerulonephritis [AGN])

    Time frame: up to 8 months after the first vaccination

Secondary outcomes

  1. Median value of each safety laboratory parameter assessed 7 days after each vaccination

    Time frame: 7 days after each vaccination

  2. Median change from baseline to 7 days after each vaccination for each safety laboratory parameter

    Time frame: 7 days after each vaccination

  3. Serum IgG geometric mean titer (GMT) at each scheduled immunogenicity sample collection visit for each vaccine antigen (SLO, C5a pep, SpyAD, GAC)

    Time frame: Prior to each vaccination, 1 month after each vaccination and Month 8

  4. Serum IgG geometric mean fold rise (GMFR) from baseline to each scheduled post-vaccination immunogenicity sample collection visit for each vaccine antigen (SLO, C5a pep, SpyAD, GAC)

    Time frame: Prior to each vaccination, 1 month after each vaccination and Month 8

  5. Percentage of participants achieving serum IgG ≥2-fold increase from baseline at each scheduled post-vaccination immunogenicity sample collection visit for each vaccine antigen (SLO, C5a pep, SpyAD, GAC)

    Time frame: 1 month after each vaccination and Month 8

  6. Percentage of participants with serum IgG ≥ LLOQ of the assay at each scheduled immunogenicity sample collection visit for each vaccine antigen (SLO, C5a pep, SpyAD, GAC)

    Time frame: Prior to each vaccination, 1 month after each vaccination and Month 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Sharing of data will require execution of a data-sharing agreement.

Access criteria: Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 1, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07616934
Lead sponsor
Vaxcyte, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 1, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Clinical Development
Contact
Clinicaltrialsgov@vaxcyte.com
650-837-0111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion